Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models

por Tuyaa-Boustugue, Pascale, Jantzen, Ingrid, Zhang, Haoyue, Young, Sarah P., Broqua, Pierre, Tallandier, Mireille, Entchev, Eugeni
Publicado 2023

Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models

por Entchev, Eugeni, Jantzen, Ingrid, Masson, Philippe, Bocart, Stephanie, Bournique, Bruno, Luccarini, Jean-Michel, Bouchot, Andre, Lacombe, Olivier, Junien, Jean-Louis, Broqua, Pierre, Tallandier, Mireille
Publicado 2020

The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis

por Wettstein, Guillaume, Luccarini, Jean‐Michel, Poekes, Laurence, Faye, Patrick, Kupkowski, Francine, Adarbes, Vanessa, Defrêne, Evelyne, Estivalet, Céline, Gawronski, Xavier, Jantzen, Ingrid, Philippot, Alain, Tessier, Julien, Tuyaa‐Boustugue, Pascale, Oakley, Fiona, Mann, Derek A., Leclercq, Isabelle, Francque, Sven, Konstantinova, Irena, Broqua, Pierre, Junien, Jean‐Louis
Publicado 2017